Preparations in treatment of psoriasis patients with concurrent metabolic syndrome: efficiency predictors and potential risks (review of literature)
Abstract
The review covers literature data on treatment of psoriasis patients with concurrent metabolic syndrome by genetic engineering preparations of biologic therapy. Special attention is paid to indications for genetic engineering preparations of biologic therapy, differential selection of such preparations for patients to decrease risks of the disease deterioration.
About the Authors
E. A. Rosete-Pidal
Central state medical academy of department of presidential affairs of the Russian Federation
Russian Federation
Russian Federation
L. S. Kruglova
Central state medical academy of department of presidential affairs of the Russian Federation
Russian Federation
Russian Federation
E. S. Ponich
Central state medical academy of department of presidential affairs of the Russian Federation
Russian Federation
Russian Federation
S. A. Chorbinskaja
Central state medical academy of department of presidential affairs of the Russian Federation
Russian Federation
Russian Federation
E. V. Filatova
Central state medical academy of department of presidential affairs of the Russian Federation
Russian Federation
Russian Federation
References
1. Бутрова С.А., Дзгоева Ф.Х. Висцеральное ожирение - ключевое звено метаболического синдрома // Ожирение и метаболизм. - 2004. - № 1. - С. 10-16
2. Дегтярев О.В., Меснянкина О. А. Патогенетическая роль нарушений липидного профиля при псориазе // Росс. ж-л кожных и венерич. болезней. - 2015. - № 18 (1). - С. 30-33.
3. Кочергин Н.Г., Потекаев Н.Н., Смирнова Л.М., Серов Д.Н., Олисова О.Ю., Бабушкин А.М. Наш первый опыт применения адалинумаба при псориазе. // Росс. ж-л кожных и венерич. болезней. - 2012. - № 5. - С. 37-41.
4. Кунгуров Н.В., Филимонкова Н.Н., Голубцов В.И., Корхмазова С.А. Генетические факторы этиологии и патогенеза псориаза // Вестн. дерматологии и венерологии. - 2011. - № 1. - С. 23-27.
5. Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. - М.: МДВ, 2014. - 264 с.
6. Фалько Е.В., Хышиктуев Б.С. Нарушения липидного обмена при псориатической болезни // Дальневост. мед. ж-л. - 2009. - № 2. - С. 118-122.
7. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. - 5-е изд. - М.: Деловой экспресс, 2016. - 768 с.
8. Al-Mutairi N., Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial // Expert Opinion on Biological Therapy. - 2014. - 14 (6). - 749-756.
9. Armstrong A.W., Robertson A.D., Wu J., Schupp C., Lebwohl M.G. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011 // JAMA Dermatol. - 2013. - 149 (10). - P. 1180-1185.
10. Augustin M., Reich K., Glaeske G., Schaefer I., Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany // ActaDermato - Venereologica. - 2010. - 90 (2). - P. 147-151.
11. Baltabayev M.A. Immun system and bile acids metabolism in psoriatic patients. 20th World Congress of Dermatology: Paris. - 2002. - book II, 1S750: abstr. 1941.
12. Boehncke W.H., Boehncke S. Research in practice: the systemic aspects of psoriasis // J. Dtsch. Dermatol. Ges. - 2008. - 6 (8). - P. 622-625.
13. Del Giglio M., Gisondi P., Tessari G., Girolomoni G. Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: a randomized, investigator-blinded study // Dermatology. - 2012. - 224. - P. 31-37.
14. Drateln C.R., Martines-Abundis E., Balcazar-Munor B.R., Bustos-Saldana R., Gonzales-Ortis M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis // J. Am. Acad. Dermatol. - 2003. - 48 (6). - P. 882-885.
15. Farber E.M., Nall M.L. The natural history of psoriasis in 5,600 patients // Dermatologica. - 1974. - 148 (1). - P. 1-18.
16. Fry L. Psoriasis. British Journal of Dermatology. - 1988. - 119 (4). - P. 445-461.
17. Gelfand J.M., Stern R.S., Nijsten T., Feldman S.R., Thomas J., Kist J., Rolstad T., Margolis D.J. The prevalence of psoriasis in African Americans: results from a population-based study // Journal of the American Academy of Dermatology. - 2005. - 52 (1). - P. 23-26.
18. Gisondi P., Conti A., Galdo G., Piaserico S., De Simone C., Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study // British J of Dermatology. - 2013. - 168 (5). - P. 1124-1127.
19. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis // The Lancet. - 2007. - 370 (9583). - P. 263271.
20. Guenther L., Gulliver W. Psoriasis comorbidities // J Of Cutaneous Medicine And Surgery. - 2009. - 13 (2). - P. 77-87.
21. Herron M.D., Hinckley M., Hoffman M.S., Papenfuss J., Hansen C.B., Callis K.P., Krueger G.G. Impact of obesity and smoking on psoriasis presentation and management // Archives of Dermatology. - 2005. - 141 (12). - P. 1527-1534.
22. Holzer M., Wolf P., Inzinger M., Trieb M., Curcic S., Pasterk L., Weger W., Heinemann A., Marsche G. Anti-psoriatic therapy recovers high-density lipoprotein composition and function // J of Investigative Dermatology. - 2014. - 134 (3). - P. 635-642.
23. Johnson-Huang L.M., Lowes M.A., Krueger J.G. Putting together the psoriasis puzzle: an update on developing targeted therapies // Disease Models and Mechanisms. - 2012. - 5. P. 423-433.
24. Kacalak-Rzepka A., Kiedrowicz M., Maleszka R. Analysis of the chosen parameters of metabolic status in patients with psoriasis // Ann. Acad. Med. Stetin. - 2013. - 59 (2). - P. 12-17.
25. Kimball А.В., Leonardi С., Stahle М., Gulliver W., Chevrier M., Fakharzadeh S., Goyal K., Calabro S., Langholff W., Menter A. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR) // British J of Dermatology. - 2014. - 171 (1) - P. 137-147.
26. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey // Archives of Dermatology. - 2001. - 137 (3). - P. 280-284.
27. Love T.J., Qureshi A.A., Karlson E.W., Gelfand J.M., Choi H.K. et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006 // Arch. Dermatol. - 2011. - 147 (4). - P. 419-424.
28. Nickoloff B.J., Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities // The J of Clinical Investigation. - 2004. - 113 (12). - P. 1664-1675.
29. Pietrzak J., Chodorowska G. Psoriasis and serum lipid abnormalities // Dermatologic Therapy. - 2010. - 23 (2). - P. 160-173.
30. Sinead M. Langan, Nicole M. Seminara, Daniel B. Shin, Andrea B. Troxel, Stephen E. Kimmel, Nehal N. Mehta, David J. Margolis, Joel M. Gelfand. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom // J of Investigative Dermatology. - 2012. - 132. - P. 556-562.
31. Sterry W., Strober B. E., Menter A.; International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review // British J of Dermatology. - 2007. - 157 (4). - P. 649-655.
32. Torii H., Nakagawa H. Questionnaire survey of perceived satisfaction with treatment of patients with psoriasis // The Japanese J of Dermatology. - 2013. - 123. - P. 1935-1944.
Review
For citations:
Rosete-Pidal E.A., Kruglova L.S., Ponich E.S., Chorbinskaja S.A., Filatova E.V. Preparations in treatment of psoriasis patients with concurrent metabolic syndrome: efficiency predictors and potential risks (review of literature). Russian Journal of Occupational Health and Industrial Ecology. 2017;(8):33-36. (In Russ.)
Views:
305
Email this article 
